Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.

European journal of endocrinology - 1 Sept 2016

Tiedje Vera, Ting Saskia, Walter Robert Fred, Herold Thomas, Worm Karl, Badziong Julia, Zwanziger Denise, Schmid Kurt Werner, Führer Dagmar

Abstract excerpt

OBJECTIVE: Medullary thyroid carcinoma (MTC) occurs sporadically in 75% of patients. Metastatic disease is associated with significantly poorer survival. The aim of this study was to identify prognostic markers for progressive MTC and oncogenic factors associated with response to vandetanib therapy. DESIGN AND METHODS: Clinical courses of 32 patients with sporadic MTC (n=10 pN0cM0, n=8 pN1cM0, n=14 pN1cM1) were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Medullary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperidines

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-ret

Share to Quinazolines

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 27283290
DOI: 10.1530/EJE-16-0252

Genes

RET
BRAF
FGFR2
FGFR3
FLT1
FLT4
PDGFRA
VEGFB
VEGFC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.PMID 27283290Read ↗

Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease AggressivenessSemantic proximity Read ↗

Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.Semantic proximity Read ↗

Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectivesSemantic proximity Read ↗

Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis.Semantic proximity Read ↗

Sporadic and familial medullary thyroid carcinoma: state of the art.Semantic proximity Read ↗

Medullary Thyroid Cancer: Molecular Biology and Novel Molecular TherapiesSemantic proximity Read ↗

MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets.Semantic proximity Read ↗

Systemic treatment and management approaches for medullary thyroid cancer.Semantic proximity Read ↗

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.Semantic proximity Read ↗

Management of hereditary medullary thyroid carcinoma.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.Semantic proximity Read ↗

Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted SequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.